FDA Largely Rejects Prometheus Petition On Drug Risks

Law360, New York (October 21, 2013, 4:37 PM EDT) -- The U.S. Food and Drug Administration has told Prometheus Laboratories Inc. that it won't quickly develop regulations clarifying how rival drugmakers should craft required risk-reduction measures and downplayed concerns that unanswered questions may trigger antitrust cases, according to a letter released Monday.

In the response to a citizen petition that Prometheus lodged in May, regulators said that while they are considering initiating rulemaking or issuing guidance on so-called single, shared risk evaluation and mitigation strategies, there will be no immediate action.

However, FDA in its Oct....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.